Novo Nordisk's 25% Stock Surge Validates Pharma's Pivot to AI Platform Outsourcing
Novo Nordisk posted strong Q1 2026 earnings and a 25% 30-day stock gain after closing its internal cell therapy unit and outsourcing Parkinson's development to AI-platform firm Cellular Intelligence. NVIDIA's BioNeMo is consolidating as the compute backbone for the industry's shift. A wave of new AI drug discovery platforms signals the sector has moved from experimentation to productization.
Salvado•